Related Experiment Videos
Total lymphoid irradiation in chronic progressive multiple sclerosis
R Capra1, N Marcianó, F Mattioli
1Clinica Neurologica, Università di Brescia.
Italian Journal of Neurological Sciences
|March 1, 1992
Summary
Total lymphoid irradiation (TLI) did not halt disability progression in severe chronic progressive multiple sclerosis (MS) patients over four years. While generally well-tolerated during treatment, side effects after TLI worsened quality of life.
Area of Science:
- Neurology
- Immunology
- Radiation Oncology
Background:
- Multiple sclerosis (MS) is a progressive neurological disease.
- Current treatments for severe chronic progressive MS have limitations.
- Total lymphoid irradiation (TLI) is an immunosuppressive therapy.
Purpose of the Study:
- To evaluate the clinical efficacy of TLI in severe chronic progressive MS.
- To assess the safety and side effects of TLI in MS patients.
Main Methods:
- Six patients with severe chronic progressive MS received TLI.
- Clinical efficacy and side effects were monitored over a four-year follow-up period.
Main Results:
- Continuous disability progression was observed in all patients during follow-up.
- Side effects during TLI were well-tolerated.
- Post-TLI side effects led to a reduced quality of life.
- One patient experienced a fatal outcome due to pneumonia.
Conclusions:
- TLI did not demonstrate efficacy in reducing disability worsening in this cohort of MS patients.
- The observed side effects suggest potential risks associated with TLI in MS management.
- Further research is needed to explore alternative or refined immunomodulatory strategies for progressive MS.